• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • T Regulatory Cell Therapies
      • SOD1 Therapies & Trials
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • Diagnostic Delay (in development)
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Meeting
    • Allied Professionals Forum
    • Alliance Webinars
    • ALS/MND Connect
    • Global Day
    • March of Faces
    • Patient Fellows Program
    • Global CRLI
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Recommendations for Trial Sponsors

Clinical trials are the most reliable – and ultimately the fastest – way to translate promising laboratory science into new and better ways to treat and care for people living with ALS/MND. Researchers use clinical trials to find out whether new treatments are safe and beneficial for people living with ALS/MND. Clinical trials also help find better ways to prevent, detect and diagnose ALS/MND; and improve quality of life through things like assistive technologies or social support. 

Participation of people living with ALS/MND is essential for clinical research. Individuals who enroll in a clinical trial are contributing to improved care for everyone living with the disease. Participation often comes with a commitment and burden to the person living with ALS/MND, and caregivers and families. Participating in trials may require individuals living with ALS/MND to travel long distances to trial sites, make more frequent trips than their care typically involves, adjust their standard of care medications, and undertake considerable time and financial commitments. Additionally, people living with ALS/MND are bearing the physical risks and psychological burden of being on an experimental therapy or placebo.

Trial sponsors have the responsibility towards people living with ALS/MND to do the right thing given the sacrifice and toll it takes to participate in often multi-year trials.

The International Alliance’s Scientific Advisory Council offers the following five recommendations that a trial sponsor should do after the clinical trial is complete to ensure the expectations of participants are met.

1. Disseminate the results of the trial quickly and responsibly: Trial sponsors should promptly convey the results of the trial to the community, regardless of whether the results are positive or negative.

Most sponsors provide top-line results through a press release. However, we recommend that additional approaches, such as directly contacting trial participants, publishing in peer-reviewed publications, presenting at scientific meetings, and holding patient webinars, should be undertaken to inform trial participants of the results of the study.

Communicating trial results in ALS/MND requires a balance of transparency and sensitivity. Below are some suggestions on how to structure the communication:

  • Trial sponsors should present findings clearly and factually, avoiding overly optimistic language that can unintentionally foster false hope.
  • When sharing biomarker results, sponsors should clearly communicate the biomarker’s context of use, its potential relevance to disease progression or treatment response, and whether it is a novel discovery, ensuring expectations are grounded in the current stage of validation and practical applicability.
  • Sponsors should emphasize what the data definitively show, clearly acknowledge limitations and where post hoc analysis is used, and frame early-phase results as part of an ongoing scientific process rather than a breakthrough.
  • Including patient advocates or clinicians in communication planning can guide messaging that resonates with the ALS/MND community while fostering realistic expectations. While social media has a place in creating awareness of clinical research and its outcomes, the use of influencers by sponsors to promote investigational therapies is strongly discouraged.

2. Share data and samples with the research community: Many people living with ALS/MND participate in trials with the expectation that their samples and data be widely used for research. Data and sample sharing is not just good practice, but in the health research context, it allows us to replicate, validate or develop new hypotheses and leads to more research engagement and improvement of patient care.

Sponsors should ensure that appropriate consent and deidentification processes are in place, so that data and samples can be shared, and that data ownership and data security are safeguarded. Sponsors should also promptly share data to open-source platforms and share biosamples through biorepositories whenever possible and authorized by the participants.

3. Clear guidance on access to treatment outside of the blinded trial: When clinical trials end, many people living with ALS/MND continue to get access to experimental treatment under an open label extension (OLE) or compassionate use (also known as Expanded Access, or EA). EA may also be available, unattached to a specific trial, in any phase of drug development.

Sponsors need to be clear upfront if they will be providing long-term access to experimental therapy through an OLE or EA pathway and for how long. They also need to be clear as to how participants will be selected, regardless of whether they were participants in the blinded trial or not. Clinics and telehealth organizations offering EA should inform prospective participants in advance if EA spots are limited, helping them avoid unnecessary time and expenses to become eligible through that site or organization.

We concede that for many sponsors, OLE and EA programs may be cost prohibitive. We recommend that sponsors take these costs into consideration when they are fundraising or building capital for the blinded trial so that such programs can be offered in a transparent, equitable, and objective manner. Sponsors should also inform participants prior to starting the blinded trial if OLE and EA programs will not be offered.

4. Share short-term and long-term development plans: ALS/MND is a devastating disease with few options for disease-modifying treatments. As such, people living with ALS/MND are always hopeful that new experimental treatments continue to move forward in the clinical trial pipeline toward approval. It is important for sponsors to describe the regulatory next steps that the company will undertake, regardless of whether the trial hit its endpoints, didn’t meet them, or there are subgroups that may have benefited from the therapy.

We recommend sponsors to do patient and lay-friendly and transparent presentations (see point#1) on what the results were and how it impacts their regulatory strategy. Sponsors should delineate if they are going to pursue regulatory approval and in which countries and which pathways are available to them to pursue future approval.

5. Unblind the participants: Blinding is essential for clinical trials to remove bias that can be caused if participants or the research team is aware of who is receiving an active or placebo treatment. Blinding is also important if a trial sponsor continues to collect data through an OLE period to assess the longer-term safety and therapeutic potential of their treatment.

However, once the trial and OLE period is officially closed, or the sponsor has an approval decision from regulatory agencies, participants should be promptly unblinded and informed as to their original treatment (e.g., drug or placebo) in the blinded portion of the trial. With the addition of numerous platform and adaptive trial designs in ALS/MND, there may be challenges in unblinding participants promptly, and in these cases participants should be informed in advance of unblinding timepoints and expectations.

International Alliance of ALS/MND Associations
April 2025


The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

  • Natalya Rybakova, Russian Charity ALS Foundation

    Natalya Rybakova, Russian Charity ALS Foundation

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

  • Susan Keldani, Les Turner ALS Foundation, USA

    Susan Keldani, Les Turner ALS Foundation, USA

  • Tammy Moore and Eddy Lefrancois

    Tammy Moore and Eddy Lefrancois

  • Camilla Heiberg Freiberg, Muskelsvindfonden, Denmark

    Camilla Heiberg Freiberg, Muskelsvindfonden, Denmark

  • Peng Yi-Wen

    Peng Yi-Wen

  • Eddy LeFrançois, Diagnosed 1992,  ALS Canada

    Eddy LeFrançois, Diagnosed 1992, ALS Canada

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • MNDaSG Group PALS & CALS, Motor Neurone Disease Association, Singapore (MNDaSG)

    MNDaSG Group PALS & CALS, Motor Neurone Disease Association, Singapore (MNDaSG)

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • 83

    83

  • Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

    Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

  • Fernando Ocampo Cardona, Colombia

    Fernando Ocampo Cardona, Colombia

  • Steven Spencer, Diagnosed 2014 , MND New Zealand

    Steven Spencer, Diagnosed 2014 , MND New Zealand

  • Sharon Corosanite, Diagnosed 2014 , ALS Hope Foundation, USA

    Sharon Corosanite, Diagnosed 2014 , ALS Hope Foundation, USA

  • João Marcos Andrietta, Diagnosed 2008 , ABrELA, Brazil

    João Marcos Andrietta, Diagnosed 2008 , ABrELA, Brazil

  • Hanne Stenmose, Muskelsvindfonden, Denmark

    Hanne Stenmose, Muskelsvindfonden, Denmark

  • Chen Yin Xue, Taiwan MND Association, Diagnosed 1995, Taiwan

    Chen Yin Xue, Taiwan MND Association, Diagnosed 1995, Taiwan

  • Denis Blais, Diagnosed 2015 , ALS Canada

    Denis Blais, Diagnosed 2015 , ALS Canada

  • Ann Nicol

    Ann Nicol

  • Wiebke Braach, Deutsche Gesellschaft für Muskelkranke, Germany

    Wiebke Braach, Deutsche Gesellschaft für Muskelkranke, Germany

  • Juvenal Bayona Romero

    Juvenal Bayona Romero

  • Dawn Morton, Diagnosed 2014 , MND Scotland, UK

    Dawn Morton, Diagnosed 2014 , MND Scotland, UK

  • Ian Gale, MND Australia

    Ian Gale, MND Australia

  • Bob Simonds and Drew O'Neil, USA

    Bob Simonds and Drew O’Neil, USA

  • Liong Ting Ngu, MND Malaysia, Diagnosed 2014

    Liong Ting Ngu, MND Malaysia, Diagnosed 2014

  • Mahmood Anwar, UK

    Mahmood Anwar, UK

  • Jose Rivero Muñoz, Diagnosed 2015, FYADENMAC, Mexico

    Jose Rivero Muñoz, Diagnosed 2015, FYADENMAC, Mexico

  • Jean

    Jean
    jean

  • Robbie Caliste, UK

    Robbie Caliste, UK

  • Liz Ogg, Diagnosed 2013 , MND Scotland, UK

    Liz Ogg, Diagnosed 2013 , MND Scotland, UK

  • Mauril Bélanger, Diagnosed 2015 , ALS Canada

    Mauril Bélanger, Diagnosed 2015 , ALS Canada

  • Steve Gallagher, ALS Society of Canada

    Steve Gallagher, ALS Society of Canada
    Picture1

  • Steve

    Steve

  • Maria Lucia Wood Saldanha, Associação Pró-Cura da ELA, Brazil

    Maria Lucia Wood Saldanha, Associação Pró-Cura da ELA, Brazil

  • Sanjay Kumar Srivastava, Asha Ek Hope Foundation for ALS/MND, Diagnosed 2018, India

    Sanjay Kumar Srivastava, Asha Ek Hope Foundation for ALS/MND, Diagnosed 2018, India

  • David Solomon, Diagnosed 2015, MND Association of England, Wales and N Ireland

    David Solomon, Diagnosed 2015, MND Association of England, Wales and N Ireland

  • Diana Fernandez, Diagnosed 2009 , Asociación ELA Argentina

    Diana Fernandez, Diagnosed 2009 , Asociación ELA Argentina

  • Timothy Holman, Switzerland

    Timothy Holman, Switzerland

  • Jo Knowlton and her dog, Scotland

    Jo Knowlton and her dog, Scotland

  • Armando González Gómez, ACELA, Colombia

    Armando González Gómez, ACELA, Colombia

  • Brian Parsons

    Brian Parsons

  • Maurice LeClerc, ALS Canada

    Maurice LeClerc, ALS Canada

  • Feng Gin Sun, Diagnosed 2014 , Shaanxi ALS Association, China

    Feng Gin Sun, Diagnosed 2014 , Shaanxi ALS Association, China

  • Cath Muir

    Cath Muir
    Cath

  • Jean Waters, Diagnosed 2004, MND Association of England, Wales and N Ireland

    Jean Waters, Diagnosed 2004, MND Association of England, Wales and N Ireland

  • Gudjon Sigurdsson, Diagnosed 2004 , MND Association of Iceland

    Gudjon Sigurdsson, Diagnosed 2004 , MND Association of Iceland

  • Marcelo Farinelli, Diagnosed 2006, ABrELA, Brazil

    Marcelo Farinelli, Diagnosed 2006, ABrELA, Brazil

  • Shay Rishoni, Diagnosed 2011 , Prize4Life, Israel

    Shay Rishoni, Diagnosed 2011 , Prize4Life, Israel

  • Bayley, Australia

    Bayley, Australia

Learn more about the March of Faces

Latest Tweets

  • Just now

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2025 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login